CNTN

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Peers: KPTI ADAG CAMP CNTX IFRX PLYX PRQR RNA TENX TLSA

| Held by: IWM VXF IWN ARKF IWC NODE AVSC RSSL ITWO UWM

Scroll to Statements

Index	RUT
Market Cap	194.35M
Enterprise Value	152.82M
Income	-80.72M
Sales	0.00M
Book/sh	8.29
Cash/sh	0.54
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	12
IPO	Jan 12, 2022

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.30
P/C	4.68
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	37.75
Current Ratio	37.75
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-2.00
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	84.14% 58.22%
Sales past 3/5Y	- -
EPS Y/Y TTM	74.31%
Sales Y/Y TTM	-
EPS Q/Q	76.93%
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	13.78%
Insider Trans	-0.94%
Inst Own	16.43%
Inst Trans	5.84%
ROA	-27.53%
ROE	-34.42%
ROIC	-17.18%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-14.60%
SMA50	-17.81%
SMA200	-23.27%
Trades

Shs Outstand	77.12M
Shs Float	66.50M
Short Float	7.04%
Short Ratio	5.21
Short Interest	4.68M
52W High	9.08 -72.25%
52W Low	1.08 133.23%
Volatility	7.96% 11.08%
ATR (14)	0.29
RSI (14)	39.68
Beta	1.44
Rel Volume	0.68
Avg Volume	898.24K
Volume	53,244

Perf Week	-9.35%
Perf Month	2.86%
Perf Quarter	-22.46%
Perf Half Y	-25.44%
Perf YTD	-16.83%
Perf Year	49.10%
Perf 3Y	-98.17%
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	5.00
Prev Close	2.57
Price	2.52
Change	-1.75%

Jun-23-26 08:15AM	Canton Strategic Holdings, Inc. Announces Launch of Locking Service to Support Network Infrastructure Providers (PR Newswire)
Jun-18-26 08:15AM	Canton Strategic Holdings, Inc. Expected to Be Included in Russell 3000 and Russell 2000 (PR Newswire) -5.37%
Jun-16-26 08:34AM	Canton Strategic Holdings, Inc. Announces Authorization of Share Repurchase Program (PR Newswire)
May-13-26 08:15AM	Canton Strategic Holdings Reports First Quarter 2026 Financial and Operational Results (PR Newswire) +7.34%
Apr-20-26 09:15AM	Canton Strategic Holdings, Inc. Presents Quarterly Canton Network Ecosystem Update (PR Newswire)
08:10AM	Loading…
Mar-31-26 08:10AM	Canton Strategic Holdings Reports Full Year 2025 Financial and Operational Results (PR Newswire) +6.17%
Mar-12-26 08:00AM	BitGo to Securely Store Digital Asset Treasury Holdings for Canton Strategic Holdings, Inc. (Business Wire) -9.78%
Mar-10-26 07:30AM	Cathie Wood Bets $19 Million on 5 Beaten-Down Stocks (Barchart)
Mar-03-26 08:15AM	Canton Strategic Holdings, Inc. Chairman and CEO Mark Wendland Elected to Canton Foundation Board (PR Newswire) -10.12%
Feb-17-26 07:10AM	Tharimmune, Inc. Announces Corporate Rebrand to Canton Strategic Holdings, Inc., Marking Milestone in Canton Network Digital Asset Treasury Strategy (PR Newswire) +5.80%
Feb-06-26 08:15AM	Tharimmune, Inc. Appoints Mark Wendland Chairman of the Board and Names Angela Radkowski Chief Operating Officer (PR Newswire) +5.34%
Feb-02-26 08:15AM	Tharimmune Elects Jill Sommers and William Wiley to Board of Directors (PR Newswire) +12.07%
Jan-31-26 02:02AM	Tharimmune Shareholders Approve Directors, Warrant-Linked Share Issuances and 7M Share Plan Boost (MarketBeat)
Jan-26-26 08:15AM	Tharimmune Announces Expanded Role as Super Validator on Canton Network (PR Newswire) +9.12%
Jan-22-26 04:12PM	Tharimmune, Inc. Announces Closing of $55 Million Underwritten Registered Direct Offering (PR Newswire) +7.89%
08:45AM	Loading…
Jan-20-26 08:45AM	Tharimmune, Inc. Announces Pricing of $55 Million Underwritten Registered Offering (PR Newswire)
Dec-18-25 08:15AM	Tharimmune, Inc. Statement on DTCC's Initiative to Tokenize U.S. Treasury Securities on the Canton Network (PR Newswire) -5.93%
Dec-12-25 08:15AM	Tharimmune, Inc. Appoints Jacob Asbury as Chief Financial Officer to Advance Canton Coin Treasury Strategy (Business Wire) -5.53%
Nov-14-25 01:17PM	New Crypto Deals Put Retail at Risk After $17 Billion Wipeout (Bloomberg)
Nov-13-25 08:05AM	Tharimmune Receives Positive FDA Feedback for TH104 Prophylaxis Program Against Respiratory Depression from Fentanyl and Ultrapotent Opioids (PR Newswire) -6.52%
Nov-10-25 06:02AM	Crypto treasury companies pivot to fringe tokens, stoking volatility fears (Reuters) -12.41%
Nov-06-25 04:16PM	Tharimmune, Inc. Closes $545 Million Private Placement to Establish Canton Coin Treasury Strategy (PR Newswire)
Nov-03-25 09:54AM	Tharimmune Stock Gains 30%, on $540M Capital Raise to Build Canton Coin Treasury Strategy (CoinDesk) +8.47%
09:04AM	Tharimmune, Inc. Announces Private Placement of Approximately $540 Million Led by DRW and Liberty City Ventures to Establish Canton Coin Treasury Strategy (PR Newswire)
Aug-27-25 12:02PM	Tharimmune (THUR) Tumbles 20.7% on $5-Million Share Sale (Insider Monkey) -18.82%
Aug-25-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +63.35%
Aug-21-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +38.44%
Aug-20-25 10:30AM	BC-Most Active Stocks (Associated Press Finance) +206.84%
08:00AM	Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments (ACCESSWIRE)
Aug-13-25 08:01AM	Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl (ACCESSWIRE) -5.71%
08:00AM	Loading…
Aug-05-25 08:00AM	Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors (ACCESSWIRE) -8.27%
Aug-04-25 08:00AM	Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery (ACCESSWIRE) +7.26%
Jul-23-25 10:15PM	Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants (ACCESSWIRE) -7.83%
Jun-17-25 08:01AM	Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors (ACCESSWIRE) +9.09%
May-19-25 08:01AM	Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +7.79%
May-06-25 08:01AM	Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback (ACCESSWIRE) +5.77%
May-01-25 08:01AM	Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences (ACCESSWIRE) -10.40%
Apr-30-25 08:01AM	Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors (ACCESSWIRE) +16.89%
Apr-28-25 08:01AM	Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +13.34%
Apr-15-25 09:00AM	Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors (ACCESSWIRE)
Apr-07-25 08:00AM	Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology (ACCESSWIRE)
Mar-31-25 08:00AM	Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure (ACCESSWIRE)
Mar-04-25 07:00AM	Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology (ACCESSWIRE)
Jan-27-25 08:30AM	Tharimmune to Present at the Microcap Conference 2025 (ACCESSWIRE)
Dec-16-24 08:00AM	Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update (ACCESSWIRE)
Dec-06-24 04:15PM	Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs (ACCESSWIRE) +10.84%
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESS Newswire)
Nov-18-24 08:00AM	Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease (ACCESSWIRE) +9.22%
Nov-13-24 08:00AM	Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics (ACCESSWIRE)
Nov-04-24 09:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE) +9.67%
Oct-30-24 08:00AM	Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) +68.97%
Oct-28-24 09:00AM	Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting (ACCESSWIRE)
Oct-25-24 08:00AM	Tharimmune Announces Upcoming Conference Presentations (ACCESSWIRE)
Sep-30-24 07:00AM	Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company (ACCESSWIRE)
Sep-16-24 07:00AM	Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab (ACCESSWIRE)
Jul-22-24 08:30AM	Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board (ACCESSWIRE)
Jul-17-24 08:30AM	Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor (ACCESSWIRE) -15.40%
Jul-16-24 08:30AM	Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104 (ACCESSWIRE)
Jun-10-24 08:00AM	Tharimmune Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -33.27%
May-29-24 08:30AM	Tharimmune to Present at 2024 BIO International Convention (ACCESSWIRE) +5.91%
May-24-24 08:12AM	Why Is Tharimmune (THAR) Stock Moving Today? (InvestorPlace) -6.87%
07:16AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace)
May-22-24 07:00AM	Tharimmune Announces 1-for-15 Reverse Stock Split (ACCESSWIRE) -16.52%
May-09-24 01:55PM	THAR Stock Earnings: Tharimmune Reported Results for Q4 2023 (InvestorPlace)
May-02-24 02:33PM	Stonegate Healthcare Partners Updates Report on Transformative Therapies for Pruritus Management (Newsfile)
Apr-30-24 08:31AM	Tharimmune To Participate in Two Upcoming Investor Conferences in May (ACCESSWIRE)
Apr-29-24 09:00AM	Keynotes, Educational Panels and 96 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 30 - May 2, 2024 at the Paris Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-23-24 07:31AM	Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) (ACCESSWIRE)
Apr-15-24 08:31AM	Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics (ACCESSWIRE) -6.11%
Mar-06-24 07:00AM	Presenting on the Emerging Growth Conference 68 Day 2 on March 7 Register Now (GlobeNewswire)
Mar-05-24 08:31AM	Tharimmune to Present at the Emerging Growth Conference on March 7, 2024 (ACCESSWIRE)
07:00AM	Presenting on the Emerging Growth Conference 68 Day 1 on March 6 Register Now (GlobeNewswire)
Feb-20-24 08:01AM	Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate (ACCESSWIRE)
Feb-05-24 08:30AM	Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis (ACCESSWIRE) -6.77%
Jan-29-24 08:00AM	Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update (ACCESSWIRE)
Dec-11-23 08:01AM	Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients (ACCESSWIRE) -7.11%
Nov-30-23 04:01PM	Tharimmune, Inc. Announces Closing of $11 Million Public Offering (ACCESSWIRE) -12.32% -11.25%
09:45AM	Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management (Newsfile)
Nov-28-23 08:43AM	Why Is Tharimmune (THAR) Stock Down 70% Today? (InvestorPlace) -72.36%
Nov-27-23 09:40PM	Tharimmune, Inc. Announces Pricing of $10 Million Public Offering (ACCESSWIRE) +22.09%
08:00AM	Tharimmune Reports Positive Phase 1 Data on TH104, its Lead Therapeutic Candidate, for Chronic Pruritis in Primary Biliary Cholangitis (PBC) (ACCESSWIRE)
Nov-20-23 09:27AM	Why Is Tharimmune (THAR) Stock Down 8% Today? (InvestorPlace) -17.76%
Nov-17-23 07:00AM	Tharimmune Announces 1-for-25 Reverse Stock Split (ACCESSWIRE) +16.67%
Nov-07-23 08:20AM	Why Is Tharimmune (THAR) Stock Up 113% Today? (InvestorPlace) +64.87%
Nov-06-23 05:35PM	Tharimmune Executes Exclusive Global Licensing Agreement for Innovative Clinical Stage Asset for Chronic Pruritis (ACCESSWIRE)
Sep-22-23 08:30AM	Hillstream BioPharma Progressing Towards Acquiring Clinical Stage Asset and Announces Corporate Name Change to Tharimmune, Inc. (ACCESSWIRE)
Sep-21-23 09:35AM	Dawson James Securities Announces October Date for 8th Annual Small Cap Growth Conference (GlobeNewswire) -5.56%
Sep-11-23 11:51AM	Hillstream Enters into an Exclusive Option Agreement to Acquire a Clinical Stage Asset for Chronic Pruritis (GlobeNewswire) -8.12%
Sep-08-23 02:30PM	Hillstream BioPharma to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 (GlobeNewswire)
Aug-15-23 10:20AM	Sidoti Events, LLCs Virtual August Micro-Cap Conference (ACCESSWIRE)
Aug-09-23 08:47AM	Hillstream BioPharma to Present at the Sidoti Micro-Cap Virtual Conference on August 16-17, 2023 (GlobeNewswire)
Jul-20-23 08:00AM	Hillstream Advances Next-Gen Multispecific Antibodies for Solid Tumors with Lead HER2/HER3 Program, HSB-3215 (GlobeNewswire) +8.08%
Jul-10-23 08:47AM	Hillstream BioPharma Announces Strategic Reprioritization of Pipeline to Targeting HER2/HER3 Solid Tumors via Bispecific and ADC Antibodies and Biologics (GlobeNewswire)
Jul-06-23 08:30AM	Hillstream BioPharma Licenses Technology to Develop Proprietary HER2 and HER3 Antibody Drug Conjugates against Drug-Resistant Breast, Lung, Gastric, and Ovarian Cancers (GlobeNewswire)
May-15-23 08:47AM	Hillstream BioPharma Strengthens its Board of Directors with Appointment of Kelly Anderson (GlobeNewswire) +5.49%
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 04:05PM	Hillstream BioPharma Announces Closing of Public Offering of Common Stock (GlobeNewswire) -7.08%
08:47AM	Hillstream BioPharma to Present at Upcoming May 2023 Investor and Industry Conferences (GlobeNewswire)
Apr-27-23 09:50PM	Hillstream BioPharma Announces Pricing of Public Offering (GlobeNewswire) +53.56% -59.49%
04:00PM	Hillstream BioPharma Announces Proposed Public Offering (GlobeNewswire)

Canton Strategic Holdings, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.

CEO & Chairman of the BoardMr. Mark Wendland

PresidentMr. Mark Toomey

Chief Financial OfficerMr. Jacob Asbury

Chief Operating OfficerMs. Angela Dominy Radkowski

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Stetz Gary S.	Director	May 22 '26	Sale	3.42	87,851	300,507	146,675	May 27 06:35 PM
Stetz Gary S.	Director	May 26 '26	Sale	3.47	12,500	43,375	134,175	May 27 06:35 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Canton Strategic Holdings Inc

Upgrade your Finviz experience